The presence of resistance-associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with hepatitis C virus (HCV) genotypes 1a (G1a) and 3 (G3) with other factors of poor treatment response (ie cirrhosis, prior treatment-exposure, or HCV-RNA >800 000 IU/mL). Herein, we evaluated in a cohort of HCV G1a and G3 infected patients the prevalence of RASs at domain I NS5A using population-based sequencing and the impact of RASs on the optimization of current therapeutic strategies. The RASs considered as clinically relevant were: M28A/G/T, Q30D/E/H/G/K/L/R, L31M/V/F, H58D, and Y93C/H/N/S for G1a and Y93H for G3.
The presence of resistance-associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with hepatitis C virus (HCV) genotypes 1a (G1a) and 3 (G3) with other factors of poor treatment response (ie cirrhosis, prior treatment-exposure, or HCV-RNA >800 000 IU/mL). Herein, we evaluated in a cohort of HCV G1a and G3 infected patients the prevalence of RASs at domain I NS5A using population-based sequencing and the impact of RASs on the optimization of current therapeutic strategies. The RASs considered as clinically relevant were: M28A/G/T, Q30D/E/H/G/K/L/R, L31M/V/F, H58D, and Y93C/H/N/S for G1a and Y93H for G3.
A total of 232 patients naïve to NS5A inhibitors were included (166 G1a, 66 G3). The overall prevalence of NS5A RASs for G1a and G3 patients was low (5.5%) or null, respectively. A high proportion of patients harbored, at least, one factor of poor response (78.9% for G1a, and 75.8% for G3). Overall, the rates of patients harboring NS5A RASs in combination with any of the other factors were low and the vast majority of patients (G1a> 94% and G3 100%) could be treated with standard treatments of 12 weeks without ribavirin. In conclusion, testing NS5A RASs in specific HCV-infected populations (ie G1a & G3, cirrhosis, prior treatment experienced, HCV-RNA >800 000 IU/mL) might be useful to optimize current NS5A-based therapies avoiding ribavirin-related toxicities, and shortening treatment duration in the majority of patients.
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genotype 1a, genotype 3, HCV-infection, NS5A, RASs treatment duration (16 or 24 weeks) and/or the addition of ribavirin if some factors related with a poor treatment response are present. This is the case of HCV-infected patients with genotypes 1a (G1a) and 3 (G3) with cirrhosis, prior exposure to interferon-based regimens, high baseline HCV-RNA, and/or presence of resistance-associated substitutions (RASs) with a poorer response for NS5A inhibitors-based therapies. [1] [2] [3] In the current treatment scenario, the relevance of HCV resistance is mainly focused on the NS5A region for G1a and G3. Several studies have shown that the presence of RASs at NS5A might compromise the virological response for HCV G1a and G3 patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The impact of these RASs on treatment efficacy varies according to the presence of other factors and can be countered by prolonging the duration of treatment or adding ribavirin for some DAA combinations.
In this context, current HCV treatment guidelines highlight that the presence of NS5A RASs before treatment initiation in combination with other factors of poor response previously cited might compromise the efficacy of specific DAA combinations. Therefore, testing NS5A resistance might help to select the optimal DAA combination among patients harboring predictors of poor response and avoid unnecessarily prolong treatment duration or the addition of ribavirin in those patients in whom RASs are not present. Therefore, this strategy might avoid the toxicity related to the use of ribavirin, allow optimize treatment duration, and afford costs to the Health systems. Moreover, it is known that NS5A RAS may persist for years, which could have implications for retreatment in case of failure.
This study analyzes, the prevalence of NS5A RASs for G1a and G3 patient's naïve to NS5A inhibitors and evaluates the benefits of performing a resistance test to optimize current therapeutic strategies.
| MATERIALS AND METHODS
This is an observational study in patients with chronic hepatitis C (CHC) The statistical analysis was performed using the Statistical
Package for the Social Sciences software (SPSS 19.0, Chicago, IL).
Categorical variables are presented as number of cases or percentage.
Continuous variables are expressed as mean ± standard deviation.
| RESULTS
The study enrolled 232 CHC patients: 166 HCV G1a and 66 HCV G3.
Clinical characteristics and prevalence of baseline NS5A RASs are detailed in Table 1 . NS5A population sequencing was successfully performed for 162 of 166 patients G1a and for all G3 patients. The prevalence of clinically relevant RASs was 5.5% (9/162) in HCV G1a.
The most frequent substitution recognized was Q30H/R (5/162, 3.1%). The remaining RASs were found with a prevalence below 1%:
M28T (1/162, 0.6%), L31M (1/162, 0.6%), H58D (1/162, 0.6%), and Y93H (1/162, 0.6%). NS5A RASs were not detected among HCV G3 infected patients. 
| DISCUSSION
The present study evaluated the prevalence of RASs related with a poor response to NS5A inhibitors in 232 CHC infected patients with G1a and G3 (naïve to NS5A inhibitors), and the clinical implication of NS5A RASs testing on current HCV therapies. [4] [5] [6] [7] [8] [9] [10] [11] A total of 166 patients with G1a (21.1% with cirrhosis, 28.3% treatment-experienced, 72.7% HCV-RNA >800 000 IU/mL) and 66 G3 (25.8% with cirrhosis, 19 .7% treatment-experienced, 64.6% HCV-RNA >800 000 IU/mL) were included. The prevalence of baseline RASs to NS5A-inhibitors was 5.5% for G1a, being Q30H/R the most prevalent mutation identified (3.1%). The NS5A RAS Y93H was not recognized for any of G3 patients.
The prevalence of baseline NS5A RASs could vary according to the geographical region. In the United States, it has been described a prevalence ranging 9-12% for G1a. 5, 11, 17, 18 In Europe, recent studies have reported rates of prevalence ranging from 1.6% in Sweden to 12.5% in Italy. 19, 20 In Spain, Calleja et al 21 and Palladino et al 22 described rates of prevalence around 6%. These figures are similar to that observed in the present study. For G3, the scarce data available,
show a rate of NS5A RASs ranging 3.8-8.8%. 6, 15 Nevertheless, the information available regard the prevalence of NS5A RASs should be carefully analyzed due to the lack of a standardized method for RASs detection, the selection of NS5A RASs considered for the analysis, and the number and clinical characteristics of the patient population included among the different studies.
Otherwise, the phenotypic resistance data generated from clinical trials indicate that only those RASs that confer medium-to high-level resistance might affect to the treatment response to DAAs. In this context, the most prevalent RAS identified in this study, Q30H/R, confers a high-level resistance (>100-fold change) to NS5A
inhibitors. 1, 17 In the current treatment scenario, the presence of clinically relevant NS5A RASs among G1a and G3 patients in combination with cirrhosis, prior treatment exposure, or high HCV-RNA >800 000 IU/ mL would make necessary the use of ribavirin or extending treatment duration (16 or 24 weeks) for some regimens including NS5A
inhibitors. This is the case of grazoprevir/elbasvir, sofosbuvir/ ledipasvir, sofosbuvir/daclatasvir for G1a, and sofosbuvir/velpatasvir for G3. 2 Herein, we analyzed the impact of the results obtained in this cohort of HCV G1a and G3 infected patients in the current clinical setting. In this cohort, many patients had, at least, one factor associated with lower SVR rates (78.9% in G1a, and 75.8% in G1b).
However, since the proportion of HCV G1a and G3 patients harboring NS5A RASs is low (5.5% and 0.0%, respectively), the vast majority of them (>94%) could cure the HCV infection with 12 weeks of treatment without ribavirin when a NS5A RASs test was available.
The SVR was retrospectively analyzed in those patients with RASs, of them, half (4/8) had received a NS5A inhibitors-based therapy. Of note, only one of them had factors of poor response and therefore standard treatment was reinforced by adding ribavirin and the effect of baseline RASs was unmasked.
These figures indicate that the implementation of NS5A RASs resistance testing before the initiation of treatments including NS5A inhibitors seems to be helpful to optimize therapies and to avoid ribavirin-related toxicities, reduce treatment duration, and costs.
However, NS5A RASs testing will be mainly focused on G1a and G3 patient's populations with characteristics associated with suboptimal SVR at 12 weeks.
There are scarce data regarding the prevalence of NS5A RASs in In summary, the prevalence of NS5A RASs in this cohort of patients with HCV G1a and G3 infection was low (5.5%) or null, respectively.
However, there is a high proportion of patients harboring other factors associated with poor rates of virological response in combination with
RASs, such as cirrhosis, prior exposure to treatment, and high HCV-RNA levels. For these patients, current guidelines recommended reinforcing treatment by adding ribavirin and/or prolonging treatment duration when these mutations are present. Therefore, testing NS5A RASs in these specific populations might be useful to optimize current NS5A-based therapies avoiding ribavirin-related toxicities and shortening treatment duration in the majority of patients.
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